Search Results
Your search for 3 matches 14951 pages
Showing 7151 - 7200ESTRO 38: High–Dose Rate Brachytherapy in Localized Prostate Cancer
A single high dose of radiation that can be delivered directly to a treatment site within a few minutes is a safe and effective technique for treating men with localized, low-risk prostate cancer, according to a study presented by Tharmalingam et al at ESTRO 38, the annual congress of the ...
ESTRO 38: Radiotherapy After ABVD May Improve Survival in Advanced Hodgkin Lymphoma
Patients with advanced Hodgkin lymphoma with bulky lesions at the time of diagnosis may benefit from radiotherapy after chemotherapy, according to late-breaking results presented by Ricardi et al at ESTRO 38, the annual congress of the European Society for Radiotherapy & Oncology...
ESTRO 38: Long-Term Results of Adjuvant Radiotherapy Plus Antihormonal Treatment in Hormone Receptor–Positive Breast Cancer
Women with early-stage, low-risk, hormone receptor–positive breast cancer may be less likely to experience disease recurrence if they have radiotherapy after surgery as well as antihormonal treatment, according to results from a trial that has followed 869 women for 10 years. These findings...
Adjuvant Pelvic Radiation Therapy vs Vaginal Brachytherapy Plus Chemotherapy in Endometrial Cancer
As reported in the Journal of Clinical Oncology by Randall et al, the phase III Gynecologic Oncology Group (GOG)-0249 trial showed similar outcomes with adjuvant pelvic radiation therapy vs vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early-stage endometrial...
IMblaze370: Atezolizumab With or Without Cobimetinib vs Regorafenib in Previously Treated Advanced Colorectal Cancer
In the phase III IMblaze370 trial reported in The Lancet Oncology, Eng et al found no survival benefit with third-line atezolizumab with or without cobimetinib vs regorafenib in patients with locally advanced or metastatic colorectal cancer. Study Details The open-label trial included 363...
Adjuvant Capecitabine After Resection for Biliary Tract Cancer
In the phase III BILCAP trial reported in The Lancet Oncology, John N. Primrose, FMedSci, and colleagues found evidence that adjuvant capecitabine may improve overall survival vs observation following surgery for patients with resected biliary tract cancer. The open-label study included 447...
Hope and Fear Are Two Constants in the Lives of Patients With Cancer
A year and a half ago, when I was 33, the thought of having a life-threatening disease was unimaginable. In hindsight, the weight loss I began experiencing in the fall of 2017 should have raised concern because I’ve always had to be mindful of my diet if I wanted to lose weight. But denial can be a ...
Hematologist Francesco Lo Coco, MD, Dies in Rome at 63
Hematologist Francesco Lo Coco, MD, known for his research accomplishments in both acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL), died in Rome on March 3, 2019. He was 63. After graduating from the Medical School in Pisa, he moved to La Sapienza University of Rome in 1981....
Physician Identity and Physician Wellness Are Inextricably Linked
Imagine a 70-year-old patient who is scheduled for a pancreaticoduodenectomy. On the morning of surgery, the patient is checked in at the front desk by the “data-entry provider.” The patient is taken to the preoperative area, where the appropriate formalities are completed by multiple “bedside-care ...
Minimal Adjuvant Chemotherapy for Pediatric Hepatoblastoma Resected at Diagnosis
In an analysis from the Children’s Oncology Group phase III AHEP0731 trial reported in The Lancet Oncology, Katzenstein et al found that minimal adjuvant chemotherapy with two cycles of cisplatin, fluorouracil, and vincristine was associated with disease control in pediatric patients with...
Long-Term Follow-up: Addition of Idelalisib to Rituximab in Relapsed Chronic Lymphocytic Leukemia
In an article published in the Journal of Clinical Oncology, Sharman et al provided long-term findings of a phase III trial that examined the addition of idelalisib to rituximab in relapsed chronic lymphocytic leukemia (CLL), including findings from an extension phase of idelalisib monotherapy. The ...
How Hepatitis C Virus Screening May Improve Survival in Patients With Cancer
In 2013, the Centers for Disease Control and Prevention (CDC) and the U.S. Preventive Services Task Force (USPSTF) recommended that all people born between 1945 and 1965 undergo one-time screening for the hepatitis C virus (HCV), because the rates of HCV infection are markedly higher for baby...
First-Line Combination Treatments Improve Outcomes vs Sunitinib in Advanced Renal Cell Carcinoma
Two recently reported phase III trials have shown the benefits of combination therapy vs sunitinib in the first-line treatment in advanced renal cell carcinoma. As reported in The New England Journal of Medicine by Brian I. Rini, MD, of Cleveland Clinic Taussig Cancer Institute, and colleagues, the ...
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
GUEST EDITORS Dr. Abutalib is Assistant Director, Hematology and Hematopoietic Cell Transplantation Director, Hematopoietic Cell Transplant Apheresis Service, Cancer Treatment Centers of America, Zion, Illinois, Editor-in-Chief, Advances in Cell & Gene Therapy. Dr. Medeiros is Professor and...
ESMO Breast Cancer 2019: Outcomes in Younger Patients With Breast Cancer
Breast cancer in young women is characterized by more aggressive biologic features as compared to older patients, but outcomes are good when guideline-recommended treatments are given. European Society for Medical Oncology (ESMO) spokesperson Matteo Lambertini, MD, PhD, of IRCCS Policlinico San...
Local Consolidative Therapy Linked to Survival Benefit in Oligometastatic Non–Small Cell Lung Cancer
A retrospective analysis of nearly 200 patients treated with local consolidative therapy for oligometastatic non–small cell lung cancer (NSCLC) has found improved overall survival associated with aggressive consolidation.1 According to data presented at the 2019 Multidisciplinary Thoracic Cancers...
Final Overall Survival Analysis of the LATITUDE Trial in Newly Diagnosed, High-Risk, Metastatic, Castration-Sensitive Prostate Cancer
As reported in The Lancet Oncology by Fizazi et al, the final overall survival analysis in the phase III LATITUDE trial has shown a significant benefit with the addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) in newly diagnosed, high-risk, metastatic, ...
Phase II Study of Regorafenib in Metastatic Osteosarcoma
As reported in the Journal of Clinical Oncology by Davis et al, outcomes in the osteosarcoma cohort of the phase II SARC024 trial indicated a progression-free survival benefit with regorafenib vs placebo in previously treated metastatic osteosarcoma. Study Details The randomized...
Erlotinib Plus Bevacizumab vs Erlotinib Alone in EGFR-Positive, Advanced Nonsquamous NSCLC
In an interim analysis of the phase III NEJ026 trial reported in The Lancet Oncology, Saito et al found that the addition of bevacizumab to erlotinib improved progression-free survival in patients with EGFR-positive, nonsquamous non–small cell lung cancer (NSCLC). In the open-label...
Risk Model for Disease Progression in Asymptomatic Waldenström’s Macroglobulinemia
In a study reported in the Journal of Clinical Oncology, Bustoros et al developed a model for predicting risk of progression from asymptomatic Waldenström’s macroglobulinemia to symptomatic disease requiring treatment. The study involved 439 patients with asymptomatic...
Addition of Nab-paclitaxel to Gemcitabine and Cisplatin in Advanced Biliary Tract Cancers
In a phase II trial reported in JAMA Oncology, Shroff and colleagues found that the addition of nab-paclitaxel to standard gemcitabine and cisplatin resulted in promising outcomes in patients with unresectable locally advanced or metastatic biliary tract cancers. The study included 60 patients...
Intermittent vs Intensive PEG-Asparaginase in Pediatric Acute Lymphoblastic Leukemia
In a Scandinavian study reported in the Journal of Clinical Oncology, Albertsen et al found that use of intermittent vs intensive pegylated (PEG)-asparaginase was associated with similar efficacy and reduced asparaginase-related toxicity in pediatric acute lymphoblastic leukemia (ALL). The study...
2019 ASCO Annual Meeting Global Health Track
ASCO Annual Meeting attendees with an interest in global health will find a deep portfolio of relevant sessions in the 2019 program. A preliminary list of global health–related sessions is below; visit am.asco.org or check the 2019 iPlanner for the most updated program information, including...
Ramucirumab After Sorafenib in Advanced Hepatocellular Carcinoma: An Efficacious Therapy With Applicability Challenges
In the 2 years since the U.S. Food and Drug Administration’s (FDA) approval of regorafenib in the treatment of patients with sorafenib-refractory advanced hepatocellular carcinoma, we oncologists have witnessed a veritable avalanche of newly approved medicines for the treatment of advanced...
Ramucirumab in Sorafenib-Pretreated Patients With Advanced Hepatocellular Carcinoma
In the phase III REACH-2 trial reported in The Lancet Oncology, Andrew X. Zhu, MD, of Harvard Medical School and Massachusetts General Hospital, and colleagues found that ramucirumab improved overall and progression-free survival vs placebo in patients with advanced hepatocellular carcinoma and...
New ASCO Guidelines on Early Detection and Treatment of Colorectal Cancer in Resource-Stratified Settings
ASCO has approved two new resource-stratified guidelines aimed at improving the early detection and treatment of colorectal cancer in all resource settings. The guidelines are a continuation of ASCO’s efforts to provide evidence-based recommendations for the management of malignancies applicable...
PRIMeR Study Explores Meaning of Minimal Residual Disease in Myeloma
In a study that earned a Best Abstract Award at the 2019 Transplantation & Cellular Therapy (TCT) Meetings in Houston, minimal residual disease (MRD) negativity at 1 year after autologous hematopoietic cell transplant (HCT) and maintenance lenalidomide therapy was an independent prognostic...
Biomarkers Can Now Help Guide Treatment Selections in Breast Cancer
A growing list of biomarkers is beginning to drive targeted therapy in breast cancer, and clinicians can take advantage of these assays to make treatment selections, Debu Tripathy, MD, Professor of Medicine and Chair of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center,...
Study Finds Radiation Therapy After Surgery for Pediatric Ependymoma Improves Survival
RADIATION THERAPY immediately following surgery in children with ependymoma, the third most common pediatric brain tumor, nearly tripled survival, in a Children’s Oncology Group (COG) clinical trial led by Thomas E. Merchant, DO, PhD, Chair of the Department of Radiation Oncology at St. Jude...
Rising Rates of Six Obesity-Related Cancers Among Younger Adults
PHYSICIANS SHOULD routinely assess the body mass index (BMI) of their patients and offer counseling and/or referrals to a nutritionist or dietician to patients with a BMI of > 30 kg/m2, Ahmedin Jemal, DVM, PhD, told The ASCO Post. Those actions plus community-level policies designed to increase...
Preliminary Results Show Activity for Mesothelin‑Directed CAR T-Cell Therapy in Malignant Mesothelioma
A phase I clinical trial showed encouraging results with chimeric antigen receptor (CAR) T-cell therapy targeted to the mesothelin protein in patients with mesothelin-associated malignant pleural solid tumors—primarily, malignant mesothelioma—that had progressed following standard platinum-based...
Role of Repeat PET/CT Scans in Ensuring Accuracy of Staging of Locally Advanced NSCLC
Findings from a new study highlight the importance of timing in initial staging positron-emission tomography (PET) and/or computed tomography (CT) scans for patients with locally advanced non–small cell lung cancer (NSCLC) receiving chemoradiation therapy.1 According to data presented at the 2019...
Mitigating Frailty and Sarcopenia to Improve Treatment Outcomes in Lung Cancer
Frailty and sarcopenia are common conditions among patients with lung cancer and are linked with decreased survival as well as increased surgical complications, chemotherapy toxicity, and cost of care. If a survey of oncologists at the 2019 Multidisciplinary Thoracic Cancers Symposium is any...
DNA Rearrangement May Predict Treatment Resistance and Poor Outcomes in Multiple Myeloma
A certain type of DNA marker may predict poor outcomes in multiple myeloma, researchers at Winship Cancer Institute of Emory University have found. The marker is a particular rearrangement of chromosomes that is rarely tested for but may indicate resistance to immunomodulatory drugs such as...
Combined Crowd Innovation and AI in Producing Algorithms for Radiotherapy Targeting
In a study reported in JAMA Oncology, Mak et al found that a crowd innovation contest produced automated artificial intelligence (AI) algorithms “that replicated the skills of a highly trained physician” in segmenting lung tumors for radiotherapy targeting. The investigators also noted...
Low-Dose Tamoxifen vs Placebo in Preventing Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia
In an Italian phase III study reported in the Journal of Clinical Oncology, DeCensi et al found that tamoxifen at 5 mg/d vs placebo for 3 years reduced the risk of recurrence of breast intraepithelial neoplasia and was associated with limited toxicity. As noted by the investigators,...
Well-Deserved Attention on Lung Cancer Screening
SCREENING FOR LUNG CANCER among high-risk groups deserves the attention that Steven E. Vogl, MD, brought to it in his column At Microphone 1 in the February 10 issue of The ASCO Post. Subspecialist oncologists are not always attuned to the needs of their patients outside of their own specialty.1...
Modeling Projections of Global Cervical Cancer Control
In a modeling study reported in The Lancet Oncology, Karen Canfell, DPhil, and colleagues detailed the preventive effects on cervical cancer that could be achieved by scaled-up human papillomavirus (HPV) vaccination and cervical screening efforts with the aim of disease elimination. The major...
The Boy I Never Knew
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Dance/Movement Therapy: Getting to Feelings That Have No Words
Dance/movement therapy is a complementary modality that is being explored for symptom control and for improving the quality of life of patients with cancer, especially pediatric patients. Self-expression as well as the creative and interpersonal aspects of dance/movement therapy can help patients...
Early Studies of Two Regimens Show Benefit in High-Risk Smoldering Multiple Myeloma
MORE DATA are in to support early intervention for high-risk smoldering multiple myeloma—an early, asymptomatic entity lacking the presence of CRAB criteria (elevated calcium, renal failure, anemia, bone lesions). The latest come from two phase II studies presented at the 2018 American Society of...
Expert Point of View: Joseph Mikhael, MD
PRESS BRIEFING moderator Joseph Mikhael, MD, Professor of Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute, City of Hope Cancer Center in Phoenix, noted that traditional models are based on simplicity, and the scoring system contains few variables. “In an era...
New Model May Improve Prediction of Risk in Myelodysplastic Syndromes
A PERSONALIZED risk-prediction model for myelodysplastic syndromes (MDS) has been developed through the use of a machine-learning approach that analyzes genomic and clinical data for an individual patient. According to lead investigator Aziz Nazha, MD, of the Cleveland Clinic, the model provides...
Expert Point of View: Aaron S. Mansfield, MD
The discussant of the STELLAR trial abstract, Aaron S. Mansfield, MD, a translational scientist at the Mayo Clinic in Rochester, called the survival outcomes “very promising” for a trial that included a relatively large population of patients with the more aggressive sarcomatoid variant of...
Tumor-Treating Fields Plus Chemotherapy Improved Survival in Unresectable Malignant Pleural Mesothelioma
The addition of tumor-treating fields to standard-of-care chemotherapy has been found to be safe and effective in the treatment of unresectable malignant pleural mesothelioma. Data presented at the 2019 Multidisciplinary Thoracic Cancers Symposium showed that patients receiving the combination of...
SABR-COMET: Stereotactic Ablative Radiotherapy vs Standard Palliative Treatment in Oligometastatic Cancers
Results of the phase II SABR-COMET trial reported by Palma et al in The Lancet indicate that stereotactic ablative radiotherapy (SABR) was associated with improved survival vs standard palliative treatment in patients with oligometastatic cancers, although it was also associated with...
Shared Decision-Making in Lung Cancer Screening: Whence? Whither?
We read with interest a recent article published on ASCOPost.com, which summarized a paper on the role of shared decision-making in lung cancer screening.1,2 The summary and original report highlight a mandate by the Centers for Medicare & Medicaid Services (CMS) that bears careful...
Perioperative Therapy With FLOT vs ECF/ECX in Locally Advanced Gastric Adenocarcinoma
In the German phase II/III FLOT4 trial reported in The Lancet, Al-Batran et al found that perioperative therapy with the docetaxel-based triplet FLOT (fluorouracil [5-FU]/leucovorin, oxaliplatin, and docetaxel) was associated with improved overall survival vs ECF/ECX (epirubicin and cisplatin plus...
Doxepin or Diphenhydramine/Lidocaine/Antacid Mouthwash for Radiotherapy-Related Oral Mucositis Pain
In the phase III Alliance A221304 trial reported in JAMA, Sio et al found that doxepin mouthwash and diphenhydramine/lidocaine/antacid mouthwash reduced oral mucositis pain for the first 4 hours after administration in patients with oral mucositis pain from head and neck radiotherapy, but the...
SUNSHINE Trial: High-Dose Vitamin D May Benefit Patients With Metastatic Colorectal Cancer
Results of a small clinical trial suggest that supplementing chemotherapy with high doses of vitamin D may benefit patients with metastatic colorectal cancer by delaying progression of the disease. These findings were published by Ng et al in JAMA. Initial trial findings were reported at the 2017...
